Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer

David E Kozono,Thomas E Stinchcombe,Joseph K Salama,Jeffrey Bogart,W Jeffrey Petty,Michael J Guarino,Lyudmila Bazhenova,James M Larner,Jared Weiss,Thomas A DiPetrillo,Steven J Feigenberg,Xin Chen,Zhaowen Sun,Ilpa Nuthalapati,Lindsey Rosenwinkel,Eric F Johnson,Bruce A Bach,Yan Luo,Everett E Vokes

Lung Cancer（2021）

引用 9|浏览19

暂无评分

摘要

•Veliparib, a PARP inhibitor, enhances cytotoxicity induced by chemoradiotherapy (CRT)•This phase 1 trial investigated veliparib + CRT in unresectable stage III NSCLC.•Veliparib + CRT was well-tolerated in these patients.•MTD/RP2D was veliparib 240 mg BID + CRT, and 120 mg QD with consolidation CT.•Veliparib + CRT showed antitumor activity with an mPFS of 19.6 months.

查看译文

关键词

Veliparib,Chemoradiotherapy,Lung neoplasms,Non-small cell,Phase 1

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要